Park Avenue Securities LLC Has $939,000 Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Park Avenue Securities LLC grew its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 103.4% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 3,961 shares of the medical research company’s stock after buying an additional 2,014 shares during the period. Park Avenue Securities LLC’s holdings in IQVIA were worth $939,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the stock. First Foundation Advisors raised its holdings in IQVIA by 3.8% in the 2nd quarter. First Foundation Advisors now owns 1,161 shares of the medical research company’s stock valued at $245,000 after acquiring an additional 43 shares in the last quarter. Team Hewins LLC raised its stake in shares of IQVIA by 5.0% in the first quarter. Team Hewins LLC now owns 973 shares of the medical research company’s stock valued at $246,000 after purchasing an additional 46 shares in the last quarter. Invera Wealth Advisors LLC lifted its position in IQVIA by 0.3% in the second quarter. Invera Wealth Advisors LLC now owns 14,506 shares of the medical research company’s stock worth $3,183,000 after purchasing an additional 46 shares during the period. Covestor Ltd boosted its stake in IQVIA by 45.3% during the first quarter. Covestor Ltd now owns 154 shares of the medical research company’s stock worth $39,000 after buying an additional 48 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund increased its holdings in IQVIA by 0.3% in the 2nd quarter. Oregon Public Employees Retirement Fund now owns 15,668 shares of the medical research company’s stock valued at $3,313,000 after buying an additional 48 shares during the period. Institutional investors own 89.62% of the company’s stock.

Insider Activity

In related news, insider Eric Sherbet sold 1,300 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the transaction, the insider now owns 19,536 shares in the company, valued at $4,812,302.88. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.60% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on IQV. UBS Group lifted their target price on shares of IQVIA from $295.00 to $300.00 and gave the company a “buy” rating in a research report on Tuesday, July 23rd. Evercore ISI decreased their price objective on IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a report on Tuesday. Barclays increased their target price on IQVIA from $255.00 to $275.00 and gave the stock an “overweight” rating in a report on Tuesday, July 23rd. Morgan Stanley boosted their price target on IQVIA from $270.00 to $280.00 and gave the company an “overweight” rating in a research note on Tuesday, July 23rd. Finally, Robert W. Baird upped their price target on IQVIA from $251.00 to $256.00 and gave the company a “neutral” rating in a research report on Friday, September 20th. Five research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $266.67.

IQVIA Stock Up 0.9 %

Shares of NYSE IQV opened at $228.79 on Thursday. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 1.80. The company has a market cap of $41.69 billion, a price-to-earnings ratio of 31.26, a price-to-earnings-growth ratio of 2.18 and a beta of 1.49. IQVIA Holdings Inc. has a 12-month low of $167.42 and a 12-month high of $261.73. The firm’s 50-day simple moving average is $240.12 and its 200 day simple moving average is $232.02.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, beating the consensus estimate of $2.57 by $0.07. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The business had revenue of $3.81 billion for the quarter, compared to analysts’ expectations of $3.79 billion. During the same period in the prior year, the firm earned $2.22 earnings per share. IQVIA’s revenue was up 2.3% compared to the same quarter last year. On average, research analysts expect that IQVIA Holdings Inc. will post 10.25 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.